Clinical trials: Disease Exacerbation
Pulmonary Disease, Chronic Obstructive
Simvastatin Therapy for Moderate and Severe COPD
To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12 months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung disease (COPD) in patients with moderate to…
- Trial name
- STATCOPE (NCT01061671)
- Testing
- simvastatin
- Where
- 51 sites in United States, Canada
- Volunteers
- 885 people
- Sponsor
- University of Minnesota
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14…
- Trial name
- RESPIRE 1 (NCT01764841)
- Testing
- Ciprofloxacin DPI (BAYQ3939)
- Where
- 151 sites in United States, Argentina and 12 more
- Volunteers
- 416 people
- Sponsor
- Bayer
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Asthma
Long Term Special Drug Use Investigation of Mepolizumab
This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC).
- Trial name
- NCT03028480
- Testing
- NUCALA Injection
- Volunteers
- 1,061 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD
Exacerbations of chronic obstructive pulmonary disease (COPD) are the first cause of admission to Pulmonary Department in Italy and worldwide.
- Trial name
- NCT01125098
- Testing
- PRO-CT values
- Where
- Italy
- Volunteers
- 183 people
- Sponsor
- University of Modena and Reggio Emilia
Schizophrenia
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
- Trial name
- NCT01469039
- Testing
- ALKS 9072
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 623 people
- Sponsor
- Alkermes, Inc.
Chronic Obstructive Pulmonary Disease
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed…
- Trial name
- REACT (NCT01329029)
- Testing
- Roflumilast
- Where
- 180 sites in Australia, Austria and 19 more
- Volunteers
- 1,945 people
- Sponsor
- AstraZeneca
Asthma
Asthma Exacerbation Study
This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.
- Trial name
- NCT01086384
- Testing
- Fluticasone Furoate/GW642444, Fluticasone furoate
- Where
- 183 sites in United States, Argentina and 9 more
- Volunteers
- 2,020 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297115
- Testing
- Roflumilast
- Where
- 287 sites in United States, Canada and 6 more
- Volunteers
- 1,568 people
- Sponsor
- AstraZeneca
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Pulmonary Disease, Chronic Obstructive
Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is caused by cigarette smoking or by breathing in other lung irritants, including pollution, dust, or chemicals.
- Trial name
- LEUKO (NCT00493974)
- Testing
- Zileuton
- Where
- 18 sites in United States
- Volunteers
- 119 people
- Sponsor
- University of Minnesota
Pulmonary Cystic Fibrosis
Standardized Treatment of Pulmonary Exacerbations II
Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during which symptoms of lung infection increase and lung function decreases.
- Trial name
- STOP2 (NCT02781610)
- Testing
- Standard of care IV antibiotic(s)
- Where
- 58 sites in United States, Canada
- Volunteers
- 982 people
- Sponsor
- Chris Goss
Chronic Obstructive Pulmonary Disease, Acute Exacerbation of COPD
Effect of Blood Flow Restriction Resistance Exercises in COPDAE In-patient Rehabilitation
This is a randomised controlled trial of the blood flow restriction resistance exercise (BFR-RE) for early rehabilitation of chronic obstructive pulmonary disease acute exacerbation (COPDAE) in the Haven of Hope Hospital.
- Trial name
- NCT04448236
- Testing
- Blood flow restriction resistance exercise
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- Hospital Authority, Hong Kong
Asthma
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma…
- Trial name
- DREAM (NCT01000506)
- Testing
- Mepolizumab 750, Mepolizumab 250, Mepolizumab 75
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 621 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs.
- Trial name
- PIPE-CF (NCT01694069)
- Testing
- Piperacillin-tazobactam combination product
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- West Virginia University
Asthma
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically…
- Trial name
- NIMBLE (NCT04718389)
- Testing
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab
- Where
- 397 sites in United States, Australia and 19 more
- Volunteers
- 1,717 people
- Sponsor
- GlaxoSmithKline
Asthma
A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation
This is a double blind, controlled clinical trail testing whether three doses of 1.25 mg of nebulized levalbuterol in combination with three doses of 0.5mg of nebulized ipratropium will lead to greater bronchodilation than that…
- Trial name
- NCT00583778
- Testing
- ipratropium
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- MetroHealth Medical Center
Pulmonary Disease, Chronic Obstructive
Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
This is a 12 month randomized, open-label, parallel-group study to obtain data on the frequency and variability of exacerbations in severe and very severe Chronic Obstructive Pulmonary Disease (COPD) patients (Global Initiative…
- Trial name
- NCT00527826
- Testing
- Salmeterol / Fluticasone (50/500 µg) BID fixed combination, Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers
- Where
- 23 sites in Germany
- Volunteers
- 214 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects
Cystic fibrosis (CF) lung disease is characterized by chronic bacterial colonization and recurrent infection of the airways. Lowering the airway surface liquid (ASL) salt concentration has been shown to increase activity of salt…
- Trial name
- NCT00928135
- Testing
- Xylitol, Hypertonic saline
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Joseph Zabner
Pulmonary Disease, Chronic Obstructive
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a…
- Trial name
- NCT03345407
- Testing
- Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg
- Where
- 161 sites in United States, Argentina and 14 more
- Volunteers
- 943 people
- Sponsor
- GlaxoSmithKline